A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

Trial Details

NCT ID
NCT06017258
Phase
PHASE1
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CD371-specific/YSNVz/I-18 CAR T cells
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Subject Inclusion: Collection of T cells (Part A)
  • History of CD371+ AML
  • Any disease status is eligible for collection
  • Expression of CD371 at any level on AML blasts (any method of detection including IHC and/or flow cytometry)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →